Fast-ex­pand­ing Shang­hai Phar­ma breaks ground on $1.8B biotech park fo­cused on next-gen R&D, an­ti­body pro­duc­tion

One of Chi­na’s biggest bio­phar­ma com­pa­nies is hit­ting the ground run­ning in 2021.

Shang­hai Phar­ma­ceu­ti­cals broke ground Mon­day on a $1.8 bil­lion, 3.2 mil­lion-square-foot in­dus­tri­al park ded­i­cat­ed to R&D work in the bustling field of cell and gene ther­a­pies as well as man­u­fac­tur­ing ther­a­peu­tic an­ti­bod­ies, the firm said.

The mas­sive site is lo­cat­ed in Pudong New Area’s Zhangjiang area and will see con­struc­tion take place in two phas­es — 1.08 mil­lion square feet for the first, and 2.15 mil­lion square feet for the sec­ond. News of the ground­break­ing and ex­pan­sion project was first re­port­ed by SHINE, a dig­i­tal news out­let of the Shang­hai Dai­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER